BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL

[AussieNeil]

Here's a welcome article that explains all about BTK degraders; the next class of BTK drug after the success of the FDA approved covalent BTKis (acalabrutinib/Calquence, ibrutinib/Imbruvica and zanubrutinib/Brukinsa) and non-covalent BTKi pirtobrutinib/Jaypirca.

"Oral therapies targeting receptors in a blood cancer called chronic lymphocytic leukemia (CLL) have transformed outcomes with for those with this disease. However, for patients who experience progression of their cancer after these therapies, there are very limited effective treatment options available. Bruton’s tyrosine kinase (BTK) degraders are a new class of medications that have potential to be effective in this scenario. This review describes the mechanism of action of BTK degraders, and their pre-clinical and clinical development to date, including emerging clinical trial data. Potential future directions for the development of these agents is also discussed."

:

We focus on their development as a drug class, the up-to-date clinical data available, as well as future directions. BTK protein degraders are a novel drug class with an alternate mechanism of action (MOA), compared to cBTKis and non-covalent BTKis (ncBTKis).."

pmc.ncbi.nlm.nih.gov/articl...

I've been trying to keep up to date with BTK degraders in this reply to my Yet Another BTK inhibitor (YABTKi) post;

healthunlocked.com/cllsuppo...

Neil

[Schubert1870]

I’m hoping if and when the BTK degrader trial I was on for 7 months is FDA approved that I will be able to have the option to start up again without being bound to the lowest dosage on a trial.

[Zweistein in reply to Schubert1870]

I am still sorry that in your case no research is being done to see whether increasing the dosage will get you back on track no matter what the original study goals are.

[Schubert1870 in reply to Zweistein]

Hi Zweistein,

From what I gather after having experienced my first trial, and I don't know if this is done for all the trials out there, but each hopsital that is administering the trial I was on uses different dosage levels to see which levels are the most effective as well as side effects. I didn't have a choice, and the way I see it as a positive is that it has bought me that much more time. I do think the degrader will eventually be approved.